Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Associations of homocysteine, C-reactive protein and cardiovascular disease in patients with renal disease
Autore:
Eikelboom, JW; Hankey, GJ;
Indirizzi:
McMaster Univ, Prevent Cardiol & Therapeut Program, Hamilton, ON, Canada McMaster Univ Hamilton ON Canada Therapeut Program, Hamilton, ON, Canada
Titolo Testata:
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
fascicolo: 3, volume: 10, anno: 2001,
pagine: 377 - 383
SICI:
1062-4821(200105)10:3<377:AOHCPA>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
PLASMA TOTAL HOMOCYSTEINE; PERITONEAL-DIALYSIS PATIENTS; FOLIC-ACID SUPPLEMENTATION; HEMODIALYSIS-PATIENTS; TRANSPLANT RECIPIENTS; VASCULAR-DISEASE; ACCESS THROMBOSIS; RISK FACTOR; HYPERHOMOCYSTEINEMIA; FOLATE;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
65
Recensione:
Indirizzi per estratti:
Indirizzo: Eikelboom, JW HGH McMaster Clin, Prevent Cardiol & Therapeut Program, 237 Barton St E, Hamilton, ON L8L 2X2, Canada HGH McMaster Clin 237 Barton St EHamilton ON Canada L8L 2X2
Citazione:
J.W. Eikelboom e G.J. Hankey, "Associations of homocysteine, C-reactive protein and cardiovascular disease in patients with renal disease", CURR OP NEP, 10(3), 2001, pp. 377-383

Abstract

In the past year, evidence from epidemiological studies in patients with renal disease has confirmed associations between both elevated plasma total homocysteine concentrations and the inflammatory marker C-reactive protein with an increased risk of arteriosclerotic vascular disease. However, it remains to be determined whether lowering total homocysteine or reducing inflammation will prevent 'hard' clinical outcome events such as stroke, myocardial infarction, and vascular death. Randomized trials of homocysteine lowering are currently ongoing and should further clarify the nature of the observed association between elevated total homocysteine and cardiovascular risk in patients with or without renal disease, and whether it is causal and modifiable. There are currently no known therapeutic interventions that specifically lower C-reactive protein levels in individuals or the prevalence of elevated C-reactive protein in the population but randomized trials of anti-inflammatory therapy (e.g, using selective cyclo-oxygenase-2 inhibitors) aimed at preventing cardiovascular disease are currently being planned. Curr Opin Nephrol Hypertens 10:377-383 (C) 2001 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 05:59:32